Clinical trials, defined by meticulous randomization, bias reduction, and causal proof, are often referred to as the gold standard of medical research. But the rigor and focus that make clinical ...
Roche will propose cancer targets and Hansoh will build antibody-drug conjugates against them, with $400 million upfront and $15B+ in milestones.
Merck & Co. remains the “big dog” in the pharma industry in 2025, with roughly $64.17 billion in FY2024 revenue. It claimed the top position a year earlier. Drawing on continued Keytruda momentum, ...
Eli Lilly has agreed to acquire AtaiBeckley for $2.8 billion upfront, plus up to $1 billion in contingent value rights, in a deal that could reach $3.8 billion. The acquisition would make Lilly the ...
A team from ETH Zurich and Karolinska Institutet has developed a cross-linking MALDI mass spectrometry workflow that captures both functional response and target binding in a single assay. Drug ...
The FDA has finalized new guidelines for meetings between the FDA and sponsors or applicants relating to the development and review of drugs or biological products under the Prescription Drug User Fee ...
In November, I wrote that Lilly would likely overtake Merck by late 2026 under base-case assumptions. It happened a year early. And Lilly’s 2026 guidance of $80–$83 billion is already running ahead of ...
The international biotech sector clocked in at $1.37 trillion in 2022 despite headwinds such as slow launches, long-term drug pricing shifts and changing consumer behavior. Recent biotech ...
The biotech industry is facing a reckoning in 2023. To date, roughly 100 biopharmas have cut workers this year, matching the total number of layoffs in the sector in 2022. Many biotech startups have ...
On Monday, Novo Nordisk announced that the results from its Phase 3 trial investigating semaglutide as a treatment for Alzheimer’s “did not confirm the superiority of semaglutide versus placebo in the ...
The headline fight in FY2025 pharma happened at the very top of the leaderboard, where Keytruda held the No. 1 brand slot even as Lilly’s tirzepatide and Novo’s semaglutide passed it at the molecule ...
Switzerland-based Roche Group (OTCMKTS: RHHBY) reported total Group sales of CHF 60.5 billion for fiscal year 2024, representing a 7% increase at constant exchange rates (CER). Excluding diminishing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results